The Air France-KLM Group on Monday said it will increase its regular India flights from 20 per week in April to 30 per week in May. Regular international flights resumed on Sunday after a coronavirus pandemic-induced hiatus of approximately two years.
During the last two years, limited international passenger flights were operating between India and select countries — including France and the Netherlands — under bilateral air bubble arrangements.
"Following the resumption, Air France and KLM will progressively increase flight operations from India, starting with 20 weekly flights in April and expand frequency to 30 weekly fights in May,” the group’s press release stated.
Air France will operate from four gateways — Bengaluru, Chennai, Delhi and Mumbai — and KLM from Delhi and Mumbai, it said.
Jean-Noel Rault, Air France- KLM General Manager Indian Subcontinent, said, ”India is a strategic market for Air France and KLM, thanks to a strong VFR (visiting fiends and relatives) segment and incoming tourism we anticipate a rapid recovery that should help the industry.”
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
"We will carefully monitor the market situation as we intend to reach our pre-pandemic activity over the summer of 2022,” Rault added.